Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer.
Saved in:
| Title: | Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer. |
|---|---|
| Authors: | Brunsvig PF; Department of Clinical Cancer Research, Oslo University Hospital-The Norwegian Radium Hospital, Oslo, Norway., Guren TK; Department of Clinical Cancer Research, Oslo University Hospital-The Norwegian Radium Hospital, Oslo, Norway., Nyakas M; Department of Clinical Cancer Research, Oslo University Hospital-The Norwegian Radium Hospital, Oslo, Norway., Steinfeldt-Reisse CH; Department of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway., Rasch W; Ultimovacs ASA, Oslo, Norway., Kyte JA; Department of Clinical Cancer Research, Oslo University Hospital-The Norwegian Radium Hospital, Oslo, Norway., Juul HV; Department of Cellular Therapy, Oslo University Hospital-The Norwegian Radium Hospital, Oslo, Norway., Aamdal S; Ultimovacs ASA, Oslo, Norway., Gaudernack G; Ultimovacs ASA, Oslo, Norway., Inderberg EM; Department of Cellular Therapy, Oslo University Hospital-The Norwegian Radium Hospital, Oslo, Norway. |
| Source: | Frontiers in immunology [Front Immunol] 2020 Nov 26; Vol. 11, pp. 572172. Date of Electronic Publication: 2020 Nov 26 (Print Publication: 2020). |
| Publication Type: | Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
